2, cro concept stocks are more popular, as long as the requirements of the investor are eligible to buy. Among them, pharmaceutical cro enterprises provide technical services including new drug product development, data management, new drug application and other technical services as well as preclinical research and clinical trials, covering the entire process of new drug development. Whether or not to enter the stock market, investors should judge for themselves according to their own investment objectives and financial situation
3. As far as the market situation is concerned, cro concept stocks are considered to be superior stocks, although the overall domestic market size is still relatively small. And a lot of stock companies in the pharmaceutical sector belongs to the growth category of high-quality stocks. Note that the stock belongs to the GEM or KIC stock risk is relatively large, investors but where to buy is the need to have a strong ability to resist
1, Contract Research Organization (Contract Research Organization, CRO) originated in the United States in the early 80s of the twentieth century, it is through the form of a contract for the pharmaceutical companies, health care institutions, small and medium-sized medicine Medical device research and development enterprises, and even a variety of government funds and other institutions in basic medicine and clinical medical research and development process to provide specialized services of an academic or commercial scientific institutions.
2, for the main focus on domestic pharmaceutical companies, local CRO, China's pharmaceutical industry is relatively immature, product innovation needs less, less research budget, CRO services are mostly focused on optimizing the synthetic route of the compound, drug registration tests, hospitals into the drug after the Ⅳ phase IV clinical trials, etc., most of them do not need integrated services. Local CROs must understand their own core competencies and their own development model, and understand how to do what they do best, in order to do better than foreign companies.
3. With the development of science and technology, some large pharmaceutical companies engaged in drug research and development, are facing the emergence of new compounds and new technologies, and relying on the company's own capabilities and difficult to cope with, it will be a number of laborious and time-consuming clinical research entrusted, or the need to provide technical support and services from outside the enterprise. In particular, the mergers and layoffs in the pharmaceutical industry in recent years have objectively increased the demand for outsourced research, allowing pharmaceutical companies to keep staff numbers and overhead costs reasonably stable and at a minimum, and providing companies with a great deal of flexibility in order to prevent waste in the downturn and insufficient internal resources in the peak of the drug development period